Opus Genetics, Inc. Impairment of Intangible Assets (Excluding Goodwill)
Opus Genetics, Inc. (IRD) reported Impairment of Intangible Assets (Excluding Goodwill) of $286.13 thousand for the 156-month period ending 2014-03-31, per its 10-Q filed 2014-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2014-05-14
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2014-03-31 was $0.00.
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2013-12-31 was $0.00.
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2013-09-30 was $0.00.
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2013-06-30 was $0.00.
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2011 was $0.00.
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2010 was $0.00, a 100.00% decline from fiscal 2009.
- Opus Genetics, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2009 was $286.13K.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month | Impairment of Intangible Assets (Excluding Goodwill) 132 month | Impairment of Intangible Assets (Excluding Goodwill) 135 month | Impairment of Intangible Assets (Excluding Goodwill) 138 month | Impairment of Intangible Assets (Excluding Goodwill) 141 month | Impairment of Intangible Assets (Excluding Goodwill) 144 month | Impairment of Intangible Assets (Excluding Goodwill) 147 month | Impairment of Intangible Assets (Excluding Goodwill) 150 month | Impairment of Intangible Assets (Excluding Goodwill) 153 month | Impairment of Intangible Assets (Excluding Goodwill) 156 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $0.00 derived: 10-Q 156 month − 10-K 153 month · filed 2014-05-14 | $0.00 derived: sum of 2 quarters · filed 2014-05-14 | $0.00 derived: sum of 3 quarters · filed 2014-05-14 | $0.00 derived: sum of 4 quarters · filed 2014-05-14 | $286.13K 10-Q · filed 2014-05-14 | ||||||||
| 2013-12-31 | $0.00 derived: 10-K 153 month − 10-Q 150 month · filed 2014-03-21 | $0.00 derived: sum of 2 quarters · filed 2014-03-21 | $0.00 derived: sum of 3 quarters · filed 2014-03-21 | $0.00 derived: sum of 4 quarters · filed 2014-03-21 | $286.13K 10-K · filed 2014-03-21 | ||||||||
| 2013-09-30 | $0.00 derived: 10-Q 150 month − 10-Q 147 month · filed 2013-11-13 | $0.00 derived: sum of 2 quarters · filed 2013-11-13 | $0.00 derived: sum of 3 quarters · filed 2013-11-13 | $0.00 derived: sum of 4 quarters · filed 2013-11-13 | $286.13K 10-Q · filed 2013-11-13 | ||||||||
| 2013-06-30 | $0.00 derived: 10-Q 147 month − 10-Q 144 month · filed 2013-08-12 | $0.00 derived: sum of 2 quarters · filed 2013-08-12 | $0.00 derived: sum of 3 quarters · filed 2013-08-12 | $0.00 derived: sum of 4 quarters · filed 2013-08-12 | $286.13K 10-Q · filed 2013-08-12 | ||||||||
| 2013-03-31 | $0.00 derived: 10-Q 144 month − 10-K 141 month · filed 2013-05-09 | $0.00 derived: sum of 2 quarters · filed 2013-05-09 | $0.00 derived: sum of 3 quarters · filed 2013-05-09 | $0.00 derived: sum of 4 quarters · filed 2013-05-09 | $286.13K 10-Q · filed 2013-05-09 | ||||||||
| 2012-12-31 | $0.00 derived: 10-K 141 month − 10-Q 138 month · filed 2013-03-22 | $0.00 derived: sum of 2 quarters · filed 2013-03-22 | $0.00 derived: sum of 3 quarters · filed 2013-03-22 | $0.00 derived: sum of 4 quarters · filed 2013-03-22 | $286.13K 10-K · filed 2013-03-22 | ||||||||
| 2012-09-30 | $0.00 derived: 10-Q 138 month − 10-Q 135 month · filed 2012-11-08 | $0.00 derived: sum of 2 quarters · filed 2012-11-08 | $0.00 derived: sum of 3 quarters · filed 2012-11-08 | $0.00 derived: sum of 4 quarters · filed 2012-11-08 | $286.13K 10-Q · filed 2012-11-08 | ||||||||
| 2012-06-30 | $0.00 derived: 10-Q 135 month − 10-Q 132 month · filed 2012-08-08 | $0.00 derived: sum of 2 quarters · filed 2012-08-08 | $0.00 derived: sum of 3 quarters · filed 2012-08-08 | $0.00 derived: sum of 4 quarters · filed 2012-08-08 | $286.13K 10-Q · filed 2012-08-08 | ||||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-09 | $0.00 derived: sum of 2 quarters · filed 2012-05-09 | $0.00 derived: sum of 3 quarters · filed 2012-05-09 | $0.00 derived: sum of 4 quarters · filed 2012-05-09 | $286.13K 10-Q · filed 2012-05-09 | ||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16 | $0.00 derived: sum of 2 quarters · filed 2012-03-16 | $0.00 derived: sum of 3 quarters · filed 2012-03-16 | $0.00 10-K · filed 2012-03-16 | |||||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $0.00 derived: sum of 2 quarters · filed 2011-11-09 | $0.00 10-Q · filed 2011-11-09 | $0.00 derived: sum of 4 quarters · filed 2012-05-09 | |||||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $0.00 10-Q · filed 2011-08-09 | $0.00 derived: sum of 3 quarters · filed 2012-05-09 | $0.00 derived: sum of 4 quarters · filed 2012-05-09 | |||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-09 | $0.00 derived: sum of 2 quarters · filed 2012-05-09 | $0.00 derived: sum of 3 quarters · filed 2012-05-09 | ||||||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16 | $0.00 derived: sum of 2 quarters · filed 2012-03-16 | $0.00 10-K · filed 2012-03-16 | ||||||||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $0.00 10-Q · filed 2011-11-09 | |||||||||||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | ||||||||||||
| 2009-12-31 | $286.13K 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |